Immutep (ASX: IMM, NASDAQ: IMMP) continues to advance its immuno-oncology and autoimmune pipeline, with its lead candidate eftilagimod alpha (efti) showing encouraging results in clinical trials for ...

CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and ...

Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

Nishit Agarwal exemplifies excellence in Biomedical AI and Signal Processing with extensive experience in developing ...

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Lauryn Zahn, a comprehensive development teacher at Gibbs High School, is a product of this pipeline. Though Knoxville is ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

TuHURA Biosciences, a biotech firm, is advancing DNA-based immunotherapy for cancer. Read what warrants a Hold rating for ...

The results were stunning. So too was the nationality of the company behind them. Akeso, a biotech firm, is Chinese.

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...